Paper Details

  1. Home
  2. Paper Details

New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.

Author: AdamHeather, CalicDivna, GinAlfred S, HobanDaryl J, KarlowskyJames A, Lagacé-WiensPhilippe R S, RubinsteinEthan, SchweizerFrank, ZelenitskySheryl, ZhanelGeorge G

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Dalbavancin, oritavancin, and telavancin are new antibiotics that are effective against many multi-drug-resistant bacteria. They work by blocking cell wall synthesis, and they have long half-lives, allowing for less frequent dosing. Dalbavancin and telavancin require weekly dosing, while oritavancin can be given as a single dose. Clinical trials have shown that these drugs are as effective as standard treatments for complicated skin infections. The most common side effects are nausea, diarrhea, and injection site reactions.
Paper Details　
Original Abstract of the Article :
Dalbavancin, oritavancin and telavancin are semisynthetic lipoglycopeptides that demonstrate promise for the treatment of patients with infections caused by multi-drug-resistant Gram-positive pathogens. Each of these agents contains a heptapeptide core, common to all glycopeptides, which enables the...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.2165/11534440-000000000-00000

データ提供：米国国立医学図書館（NLM）

New Hope for Multi-Drug-Resistant Infections: Lipoglycopeptides in Focus

Multi-drug-resistant infections are a growing concern, posing significant challenges for treatment. This research reviews three new lipoglycopeptides - dalbavancin, oritavancin, and telavancin - as promising alternatives for treating infections caused by Gram-positive pathogens. The study compares the in vitro activity, pharmacokinetic properties, and clinical efficacy of these agents, highlighting their potential to overcome the challenges posed by multi-drug resistance. The authors discuss the unique mechanisms of action, pharmacokinetic profiles, and clinical applications of each lipoglycopeptide.

A New Arsenal for Combating Resistance: Lipoglycopeptides in Action

The study suggests that lipoglycopeptides offer a valuable tool for combating multi-drug resistance in Gram-positive infections. Just as a camel uses its adaptations to survive in the harsh desert, these new agents provide a way to navigate the challenges posed by resistant pathogens. The findings highlight the potential of these lipoglycopeptides to enhance treatment options and improve patient outcomes.

Antimicrobial Resistance: Understanding the Challenge and Seeking Solutions

The emergence of antimicrobial resistance is a global health concern, requiring a multifaceted approach to combat this threat. Individuals can contribute by using antibiotics responsibly, practicing good hygiene, and supporting research efforts to develop new and effective antibiotics. Remember, our collective efforts are crucial in addressing this significant challenge.

Dr.Camel's Conclusion

This research provides a comprehensive overview of three promising lipoglycopeptides that offer a new arsenal for combating multi-drug-resistant infections. Just as a camel uses its unique adaptations to survive in the challenging desert environment, these agents offer a way to navigate the challenges posed by resistant pathogens. The findings offer hope for improved treatment options and underscore the importance of continued research and innovation in the fight against antimicrobial resistance.

Date :
  1. Date Completed 2010-07-16
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

20426497

DOI: Digital Object Identifier

10.2165/11534440-000000000-00000

Related Literature

Article Analysis
・Effects of oritavancin injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.